Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Non-Current Liabilities: 2019-2024

Historic Other Non-Current Liabilities for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $3.2 million.

  • Revolution Medicines' Other Non-Current Liabilities rose 114.19% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 114.19%. This contributed to the annual value of $3.2 million for FY2024, which is 51.03% down from last year.
  • As of FY2024, Revolution Medicines' Other Non-Current Liabilities stood at $3.2 million, which was down 51.03% from $6.5 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Other Non-Current Liabilities registered a high of $6.5 million during FY2023, and its lowest value of $301,000 during FY2022.
  • Over the past 3 years, Revolution Medicines' median Other Non-Current Liabilities value was $3.2 million (recorded in 2024), while the average stood at $3.3 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 52.52% in 2022, then spiked by 2,063.46% in 2023.
  • Revolution Medicines' Other Non-Current Liabilities (Yearly) stood at $632,000 in 2020, then rose by 0.32% to $634,000 in 2021, then plummeted by 52.52% to $301,000 in 2022, then skyrocketed by 2,063.46% to $6.5 million in 2023, then crashed by 51.03% to $3.2 million in 2024.